Urol. praxi, 2015; 16(3): 106-108
Benefit (-2)proPSA and PHI for the diagnosis of prostate cancer
- 1 Ústav epidemiologie a OVZ, Lékařská fakulta Ostravské univerzity v Ostravě
- 2 Oddělení urologie, Nemocnice Havířov
The benefits of prostate-specific antigen (PSA) and its isoforms for the early diagnosis of prostate cancer (CaP) are considered with respect
to overdiagnosis and overtreatment. From the available literature it is evident that isoform (-2)proPSA and calculated prostate health index (PHI)
have greater sensitivity and specificity for the diagnosis of CaP with PSA levels of 2.0 – 10,0 ng/ml, than the determination of total PSA (tPSA) free
(fPSA), and their ratio. The implementation and expansion of PHI into clinical practice therefore, could lead to a reduction of prostatic biopsy
and overdiagnosis. Only some of the work showed a significant correlation between PHI, 2proPSA and prostate cancers with a Gleason score
≥ 7. The tests 2proPSA and PHI are not currently covered by public health insurance but are available in some laboratories for consideration.
Keywords: prostatic specific antigen, (-2)proPSA, prostate health index (PSA), carcinoma prostate
Published: June 30, 2015 Show citation
References
- Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17(2): 159-163.
Go to PubMed... - Lukeš M. Záleský M, Zachoval R, Urban M, Heráček J. Prostatický specifický antigen a karcinom prostaty. Klinická onkologie 2001; 14(4): 114-118. Http://www.linkos.cz/vzdelavani/4_01/02.php.
- Jahn JL, Giovannucci E, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer 2014; Dec 29.
Go to original source... Go to PubMed... - Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350(22): 2239-2246. Go to original source... Go to PubMed...
- Türk Z, Hollberg H, Dill T, Kaspers I, Isbarn H. Prostate cancer detection rates: Comparison of standard biopsy with promptrebiopsy and a one-time extended biopsy. Urologe A. 2015; 54(1): 28-33. doi: 10.1007/s00120-014-3648-4. Go to original source... Go to PubMed...
- Klečka J, Běhounek P, Hora M. Současné postavení PSA v diagnostice karcinomu prostaty. Urolog. praxi 2008; 9(4): 187-189.
- Wassenbauer R. Aktivní přístup k časné detekci karcinomu prostaty - co je smysluplné a co již škodlivé. Urologické Listy 2014; 12(2): 19-28.
- Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185(5): 1650-1655. Go to original source... Go to PubMed...
- Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostatecancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60(2): 214-222. Go to original source... Go to PubMed...
- Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSAimproves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57(6): 921-927. Go to original source... Go to PubMed...
- Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013; 63(6): 986-994. Go to original source... Go to PubMed...
- Král M, Hradil D, Grepl M, et al. Prostate health index (PHI) u pacientů s karcinomem prostaty a s BPH. Česká urologie 2011; 15(Suppl 2): 16-68.
- Klečka J, Hora M, Topolčan O, et al. Je proPSA více specifický marker pro detekci karcinomu prostaty. Česká urologie 2011; 15(Suppl 2): 16-68.
- Fuchsová R, Topolčan O, Vrzalova J, et al. Přínos stanovení [-2]proPSA v diferenciální diagnostice karcinomu prostaty. Česká urologie 2014; 18(1): 21-25.
- Čapoun O, Sobotka R, Soukup V, et al. Prostate health index (PHI) v primární diagnostice karcinomu prostaty. Česká urologie 2014; 18(Suppl 1): 21-109.